References
- Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–491.
- Homan MWL, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol. 2009;61:411–420.
- Anbar T, Westerhof W, Abdel‐Rahman A, et al. Evaluation of the effects of NB‐UVB in both segmental and non‐segmental vitiligo affecting different body sites. Photoderm Photoimm Photomed. 2006;22:157–163.
- Bae JM, Yoo HJ, Kim H, et al. Combination therapy with 308-nm excimer laser, topical tacrolimus, and short-term systemic corticosteroids for segmental vitiligo: a retrospective study of 159 patients. J Am Acad Dermatol. 2015;73(1):76–82.
- Mohammad TF, Al-Jamal M, Hamzavi IH, et al. The Vitiligo Working Group recommendations for narrowband ultraviolet B light phototherapy treatment of vitiligo. J Am Acad Dermatol. 2017;76(5):879–888.
- Li R, Qiao M, Wang X, et al. Effect of narrow band ultraviolet B phototherapy as monotherapy or combination therapy for vitiligo: a meta‐analysis. Photodermatol Photoimmunol Photomed. 2017;33:22–31.
- Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy. JAMA Dermatol. 2015;151(10):1110–1112.
- Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA). J Am Acad Dermatol. 2016;74(2):370–371.
- Boy MG, Wang C, Wilkinson BE, et al. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis. J Invest Dermatol. 2009;129(9):2299–2302.
- Ports W, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol. 2013;169(1):137–145.
- Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta‐analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850–856.
- Harris JE. Vitiligo and alopecia areata: apples and oranges? Exp Dermatol. 2013;22(12):785–789.
- Grimes PE. New insights and new therapies in vitiligo. Jama. 2005;293(6):730–735.
- Guerra L, Dellambra E, Brescia S, et al. Vitiligo: pathogenetic hypotheses and targets for current therapies. Curr Drug Metab. 2010;11(5):451–467.
- Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049.
- Urso B. Jak‐inhibitors and UV‐B: potential combined therapy for vitiligo. Dermatol Ther. 2017;30(5):e12531.
- Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure. J Am Acad Dermatol. 2017;77(4):675–682. e1.
- Joshipura D, Plotnikova N, Goldminz A, et al. Importance of light in the treatment of vitiligo with JAK-inhibitors. J Dermatol Treat. 2018;29(1):98–99.
- Winthrop KL, Yamanaka H, Valdez H, et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:2675–2684.
- Winthrop K, Park S, Gul A, et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(6):1133–1138.
- Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68:2612–2617.